Quantifying Knowledge of Alzheimer's Disease: an Analysis of the Psychometric Properties of the Alzheimer's Disease Knowledge Scale by García Ribas, Guillermo et al.
ORIGINAL RESEARCH
Quantifying Knowledge of Alzheimer’s Disease:
An Analysis of the Psychometric Properties
of the Alzheimer’s Disease Knowledge Scale
Guillermo Garcia-Ribas . Elena Garcı́a-Arcelay . Alonso Montoya .
Jorge Maurino . Javier Ballesteros
Received: November 16, 2020 /Accepted: January 6, 2021 / Published online: January 29, 2021
 The Author(s) 2021
ABSTRACT
Introduction: The Alzheimer’s Disease Knowl-
edge Scale (ADKS) is one of the most popular
instruments for assessing a person’s knowledge
regarding Alzheimer’s disease (AD). The objec-
tive of this study was to explore ADKS item
characteristics with item response theory (IRT)
procedures.
Methods: A noninterventional web-based study
was conducted. A nonparametric IRT procedure,
Mokken analysis, was used to explore the
underlying latent structure of the ADKS and
ADKS item characteristics regarding scalability
and violations of the monotone homogeneity
(MH) model. A random-effects meta-analysis
was implemented that combined ADKS scores
from independent studies.
Results: A total of 447 employees of a phar-
maceutical company participated in the study.
The mean ADKS score was 21.2 (SD 2.8). Mok-
ken analysis showed that most ADKS items (22
of 30) do not fit to any scale and can be con-
sidered to be scale independent. Two items (#1:
particularly prone to depression; #20: depres-
sion can be mistaken for AD) fit to a domain
relating to depression, another two items (#2:
mental exercise can prevent AD development;
#8: benefit of psychotherapy) can be related to
potential prevention and improvement, and
four items (#12: poor nutrition can make the
symptoms worse; #18: high cholesterol may
increase the risk of AD; #26: high blood pressure
may increase the risk of AD; #27: genes can only
partially account for AD development) fit to a
risk factor domain. As expected from those
results, neither the overall scale (H = 0.033) nor
its items showed appropriate scalability index
values, suggesting that ADKS does not fit to a
MH model. Eleven items showed violations of
the assumptions of the MH model. The meta-
analytical average score was 21.78 (95% CI
20.67–22.90), with healthcare professionals and
caregivers showing the highest levels of AD
knowledge.
Conclusion: Although the ADKS does not pre-
sent a unidimensional structure, its indepen-
dent items together provide a comprehensive
spectrum of information regarding AD
knowledge.
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Key Summary Points
Why carry out this study?
Lack of knowledge and misconceptions
about Alzheimer’s disease are critical
problems around the world.
Improving the public’s understanding of
Alzheimer’s disease may facilitate early
diagnosis, reduce stigma about the
disease, and prompt a discussion of the
needs of patients and their families.
What was learned from the study?
The Alzheimer’s Disease Knowledge Scale
is a self-rated questionnaire that assesses
what people know about Alzheimer’s
disease in different key domains. In
addition to its good psychometric
properties, it is an easy-to-implement and
reliable tool for evaluating knowledge
gaps in laypersons, caregivers, and
healthcare professionals.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13526369.
INTRODUCTION
Alzheimer’s disease (AD) leads to irreversible
progressive cognitive impairment. It is the most
common type of dementia, affecting millions of
people worldwide [1, 2].
Although information about cognitive
impairment has been widely disseminated
through numerous awareness campaigns and
educational programs, several studies have
revealed different gaps in the public’s knowl-
edge regarding dementia and AD [3–6]. Ade-
quate AD knowledge throughout society could
lead to earlier identification of this disorder in
the population, which would result in earlier
appropriate healthcare for people with demen-
tia and would decrease the stigma associated
with AD [3]. In addition, understanding peo-
ple’s perceptions of AD can be crucial when
carrying out specific psychosocial intervention
strategies [3].
Various instruments have been developed to
assess knowledge of dementia and AD, includ-
ing the Alzheimer’s Disease Knowledge Test
(ADKT), the University of Alabama Alzheimer’s
Disease Knowledge Test for Health Professionals
(UAB-ADKT), the Dementia Quiz (DQ), the
Knowledge about Memory Loss and Care test
(KAML-C), the Alzheimer’s Disease Knowledge
Scale (ADKS), the Dementia Knowledge Assess-
ment Tool Version 2 (DKAT2), the Dementia
Knowledge 20 (DK-20), and the University of
Jaén Alzheimer’s Care Scale (UJA ACS) [7–9].
The ADKS is one of the most widely used of
these instruments [3]. It is a 30-item question-
naire that measures what people know about
AD across seven critical knowledge domains:
risk factors (six items), symptoms (4 items),
assessment and diagnosis (4 items), disease tra-
jectory (4 items), life impact (3 items), treat-
ment and management (4 items), and
caregiving (5 items) [10]. The ADKS has ade-
quate psychometric properties and is designed
to be administered to the general public,
patients, caregivers, and healthcare profession-
als [8, 10].
We aimed to achieve a greater understanding
of the psychometric characteristics of the ADKS
by applying nonparametric item response the-
ory (IRT) procedures to the responses obtained
from an anonymous survey. To our knowledge,
this is the first time that a study has focused on
ADKS item characteristics instead of using clas-
sical approaches that rely on the reliability and
validity of the total ADKS score.
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METHODS
Study Design and Participants
A noninterventional, cross-sectional, self-com-
pleted, web-based study (the CONOCE study)
was conducted among employees of a pharma-
ceutical company in Spain (Roche Farma SA).
This study was conducted in accordance with
the Good Clinical Practice Guidelines of the
International Conference on Harmonisation
and with the ethical principles of the Declara-
tion of Helsinki. It was approved by the inves-
tigational review board of the Hospital
Universitario Ramón y Cajal, Madrid, Spain
(reference code: 372). Informed consent was
obtained from all subjects. Participants were
invited to participate from December 2019 to
February 2020.
Study Procedures
Participants answered questions regarding
demographic data and completed the ADKS.
Each ADKS item is a statement that can be
either false (value 0) or true (value 1) [10].
‘‘True’’ is the correct response for 18 items,
whereas the remaining 12 items are reverse
scored, so ‘‘false’’ is the correct response for
those items. A higher score indicates better
knowledge regarding AD.
Statistical Analyses
Continuous variables were described using
means and standard deviations, and categorical
variables using frequencies and percentages. A
nonparametric IRT procedure—Mokken analy-
sis—was used to explore the underlying mea-
surement structure of the ADKS and how well it
fits to the monotone homogeneity (MH) model,
which allows people to be ranked on AD
knowledge based on their total ADKS scores.
Among other criteria, the MH model assumes
unidimensionality of the latent construct mea-
sured with the scale, as assessed with Loe-
vinger’s scalability coefficients [11]. Scalability
coefficients describe the degree to which indi-
vidual items (Hi), pairs of items (Hij), and the
overall set of items (H) form a scale that can be
used to rank people on their ability (knowledge)
regarding the latent trait being measured (AD
knowledge). Scalability coefficients reflect the
ratio of the observed Guttman error frequency
(inadequacy with which the achievement level
is matched to the difficulty of the item being
measured) to the expected Guttman error fre-
quency (i.e., based on chance alone) for a pair of
items [12, 13]. When data fit well to the MH
model, Hi values are positive and range from
zero to 1, where a value of 1 indicates no
Guttman errors and values closer to zero indi-
cate many Guttman errors. To define an
appropriate unidimensional scale, each one of
the 30 ADKS items was required to have a scal-
ability coefficient (Hi) of C 0.30 and an overall
scale scalability index (H) of C 0.30 [14]. We
extracted the published effect sizes of the ADKS
from previous studies (mean values, standard
deviations, and sample sizes) and combined
them with our own results using a random-ef-
fects meta-analysis to arrive at an estimate of
the overall AD knowledge and how this
knowledge differed between population sub-
groups [15].
We performed the statistical analyses with R
version 4.0 (https://cran.r-project.org/) using
the libraries ‘‘mokken’’ for IRT and ‘‘metafor’’ for
the random-effects meta-analysis [11, 16, 17].
RESULTS
A total of 447 subjects participated in the study.
Most participants were aged between 18 and
50 years (78%), female (65%), and had a bach-
elor’s or master’s degree (89%). Forty-two
(9.4%) participants reported having a first-de-
gree relative with AD. Demographic character-
istics of the sample are shown in Table 1.
Overall AD Knowledge
The mean ADKS score was 21.2 (SD 2.8; 95% CI
20.9–21.4). For four items (caregiving domain:
‘‘informed decisions’’ and ‘‘difficulties with self-
care;’’ risk factors domain: ‘‘at risk for high
blood pressure’’ and ‘‘at risk for high choles-
terol’’), less than 50% of the answers were
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correct. Figure 1 shows the ADKS items ranked
by percentage of correct answers (‘‘percent cor-
rect’’) after reversing the scores for inverse
items.
Figure 2 shows the frequency distribution of
scores along the observed range (13–29 points);
50% of the observations occur between the
score values of 19 and 23 (which therefore cor-
respond to the 25% and 75% percentiles of the
ADKS score distribution, respectively).
Underlying Structure of the ADKS
and Item Characteristics
Most of the ADKS items (22 of 30) do not fit to
any scale and can be considered to be scale
independent. Two items (#1 and #20) fit to a
knowledge domain related to depression,
another two items ( #2 and #8) are related to AD
prevention and recovery, and four items (#12,
#18, #26, and #27) fit to a knowledge domain
related to risk factors. Table 2 shows the results
of the automated item selection procedure
(AISP) that was implemented to ascertain the
knowledge domains covered by the ADKS in the
current survey.
As expected from those results, neither the
overall scale (H = 0.033) nor its items showed
appropriate scalability indices. No item had a
scalability index Hi C 0.30, and indices were in
fact quite low, suggesting that the ADKS does
not fit a MHmodel. Moreover, 11 items violated
assumptions of the MH model (Table 2).
Meta-analysis of the ADKS Scores
Table 3 shows the main characteristics and
effect sizes of the studies that have reported
ADKS mean scores (including the present
study). Figure 3 displays a forest plot with indi-
vidual and combined ADKS scores. The com-
bined result has a relatively high mean score
(mean 21.78; 95% CI 20.67–22.90) that differs
significantly among subgroups (Q test = 11.35
on 4 df; p value = 0.02), with health profes-
sionals presenting the highest mean score (11
data points, mean ADKS = 22.9), followed clo-
sely by caregivers (3 data points, mean ADKS =
21.6). A study conducted by Baral et al. found
that students obtained the lowest scores (ADKS
score = 15.4), whereas the subgroup of health
professionals yielded the highest scores in a
study by Carpenter et al. (ADKS score = 27.4)
[10, 18].
DISCUSSION
The ADKS belongs to a group of psychometric
scales that aim to assess knowledge regarding
AD, as this can assist with the development of
psychoeducational curricula and interventions
for dementia care [7]. The original validation of
the ADKS included different populations in the
USA (college students, older adults with no
cognitive impairment, dementia caregivers, and
healthcare professionals), and the scale was also
applied to or validated by studying college stu-
dents in South Korea and Nepal, caregivers in
the Netherlands, the United Kingdom, and













Vocational training 26 5.8
Bachelor’s degree or equivalent 167 37.4
Master’s degree or equivalent 203 45.4
PhD or equivalent 28 6.3
AD caregiver 42 9.4
AD Alzheimer’s disease
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South Korea, and healthcare professionals in
Australia, Brazil, China, India, Malaysia, and
Spain [8, 10, 18–27]. It was also administered to
laypeople in Brazil, and was included as a
knowledge resource on the website of the Alz-
heimer’s Association in the USA [26, 28].
Despite some criticisms of the ADKS that are
linked to dichotomous item assessment,
reverse-scored items, and a likely ceiling effect
for some items, this is currently one of the few
validated scales to be used either at the inter-
vention planning stage or as a signal or out-
come measure when evaluating interventions
or the overall knowledge of dementia [7, 8, 29].
Because the ADKS was designed to estimate the
overall knowledge regarding AD, not an
underlying construct or dimension, several
common psychometric statistics such as inter-
nal reliability or analyses of dimensional struc-
ture are not as relevant as they might be to
other scales that are used to evaluate the effec-
tiveness of interventions [7, 8].
Our study shows that the range of percent
correct values for ADKS items and the near-
symmetric distribution of overall scores may
support its usefulness for relatives of people
with cognitive impairment who are seeking a
neurological evaluation, and to guide the psy-
choeducational efforts of dementia support
groups [10]. However, the results of the IRT
approach do not support scale unidimension-
ality or the ranking of subjects across a contin-
uum of AD knowledge. The AISP indicates that
the underlying structure of the ADKS does not
fit the originally theorized domains. It instead
suggests that items are independent, which is
relevant for a general knowledge scale that is
used to detect knowledge gaps, but not for
ranking individuals.
Carpenter et al. [10] developed the ADKS in
2009 to incorporate new scientific understand-
ing about AD into the ADKT. All measures
require periodic updates to keep pace with
developments and new information emerging
from the rapidly evolving field of cognitive
disorders. In their systematic review of AD
knowledge outcome measures, Spector et al.
recommend the development of a
Fig. 1 Alzheimer’s Disease Knowledge Scale: correct answers
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contemporary instrument that incorporates
items relating to biopsychosocial and patient-
centered models of AD care [7]. Our results do
not support the use of the total ADKS score to
meaningfully rank people according to their AD
knowledge, as the data did not fit with the MH
model. However, even though the IRT results
indicate that the ADKS is not suitable for eval-
uating people at the individual level, it does not
directly follow that group mean scores based on
knowledge accrued from multiple independent
items are not suitable for comparing population
subgroups in terms of their AD knowledge, as
our meta-analytical results show. In fact, what
might be argued is that the ADKS is a useful
outcome measure for evaluating the effective-
ness of interventions. When Hattink et al.
evaluated an e-learning course for dementia
caregivers, they did not find a significant dif-
ference between subjects randomized to the
experimental psychoeducational intervention
(n = 37, mean ADKS score = 24.37, SD = 2.94)
and those randomized to the control interven-
tion (n = 46, mean ADKS score = 24.39, SD =
2.90) [20]. The mean difference (MD) was not
significantly different between groups (MD
- 0.02, 95% CI - 1.30 to 1.26) and did not
show a significant change at four months from
baseline (n = 83, mean ADKS score = 24.28,
SD = 3.35). However, even given the serious
doubts regarding the use of ADKS as an out-
come measure to evaluate interventions,
knowledge of the correctness of responses may
be useful when designing and developing
interventions aimed at improving AD knowl-
edge among caregivers and health profession-
als—aims that also guided the development of
the ADKS [10].
This study has several limitations. There is
participant self-selection bias; it is possible that
the survey tended to attract the most motivated
respondents or those who were most knowl-
edgeable about AD. In addition, carrying out
the study in only one company may have lim-
ited the generalizability of the findings to other
healthcare communities, or even the general
population.
Fig. 2 Alzheimer’s Disease Knowledge Scale: distribution of scores
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Table 2 Correct answers, results from the Mokken automated item selection procedure, scalability coefficients, and
monotone homogeneity model violation counts for the Alzheimer’s Disease Knowledge Scale (n = 447)








1. People with AD are particularly prone to depression 327 (73) 3 0.057 0
2. It has been scientifically proven that mental exercise can prevent a
person from getting AD
334 (75) 2 0.047 1
3. After symptoms of AD appear, the average life expectancy is
6–12 years
249 (56) 0 0.015 0
4. When a person with AD becomes agitated, a medical examination
might reveal other health problems that caused the agitation
277 (62) 0 - 0.006 1
5. People with AD do best with simple instructions, giving one step
at a time
432 (97) 0 0.003 1
6. When people with AD begin to have difficulty taking care of
themselves, caregivers should take over right away
156 (35) 0 0.045 1
7. If a person with AD becomes alert and agitated at night, a good
strategy is to try to make sure that the person gets plenty of
physical activity during the day
274 (61) 0 - 0.004 1
8. In rare cases, people have recovered from AD 398 (89) 2 - 0.002 2
9. People whose AD is not yet severe can benefit from psychotherapy
for depression and anxiety
398 (89) 0 0.054 1
10. If trouble with memory and confused thinking appears suddenly,
it is likely due to AD
283 (63) 0 0.019 0
11. Most people with AD live in nursing homes 334 (75) 0 - 0.008 1
12. Poor nutrition can make the symptoms of AD worse 385 (86) 1 0.073 0
13. People in their 30s can have AD 341 (76) 0 0.039 0
14. A person with AD becomes increasingly likely to fall down as the
disease gets worse
377 (84) 0 0.031 0
15. When people with AD repeat the same question or story several
times, it is helpful to remind them that they are repeating
themselves
343 (77) 0 0.034 0
16. Once people have AD, they are no longer capable of making
informed decisions about their own care
203 (45) 0 0.063 0
17. Eventually, a person with AD will need 24 h supervision 365 (82) 0 0.006 1
18. Having high cholesterol may increase a person’s risk of
developing AD
149 (33) 1 0.092 0
19. Tremor or shaking of the hands or arms is a common symptom
in people with AD
340 (76) 0 - 0.006 3
Neurol Ther (2021) 10:213–224 219
CONCLUSION
Lack of information and misconceptions about
AD are still critical problems. Whereas the ADKS
does not show the characteristics and dimen-
sionality expected of a scale whose aim is to
evaluate a nonobservable latent factor or con-
struct, it does present a set of items that toge-
ther contribute to the overall knowledge of AD,
and so it might be useful for evaluating knowl-
edge gaps regarding AD. As originally described,
the ADKS can be used with laypeople or care-
givers to determine what they know about AD,
and by healthcare professionals and support
groups to guide psychoeducational efforts.
Table 2 continued








20. Symptoms of severe depression can be mistaken for symptoms of
AD
288 (64) 3 0.060 0
21. AD is one type of dementia 297 (66) 0 - 0.002 0
22. Trouble handling money or paying bills is a common early
symptom of AD
335 (75) 0 0.048 0
23. One symptom that can occur with AD is believing that other
people are stealing one’s things
334 (75) 0 0.075 0
24. When a person has AD, using reminder notes is a crutch that can
contribute to decline
301 (67) 0 0.038 0
25. Prescription drugs that prevent AD are available 410 (92) 0 0.015 0
26. Having high blood pressure may increase a person’s risk of
developing AD
149 (33) 1 0.064 0
27. Genes can only partially account for the development of AD 409 (92) 1 0.098 0
28. It is safe for people with AD to drive as long as they have a
companion in the car at all times
412 (92) 0 0.005 1
29. AD cannot be cured 424 (95) 0 0.052 0
30. Most people with AD remember recent events better than things
that happened in the past
354 (79) 0 0.033 0
An AISP value of zero denotes an item that does not fit to any scale
AD Alzheimer’s disease, AISP automated item selection procedure, MH monotone homogeneity
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